Soleus Capital Management, L.P.

CIK 0001802630 · GREENWICH, CT · Quarter end: 2026-06-30 · Filed on: 2026-08-11 · Open the SEC source

Soleus Capital Management, L.P. reported 97 positions worth $2.90B as of June 30, 2026 (13F filed August 11, 2026). Largest holding: KRYS (12.0%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$2.90B
2026 Q2
Positions
97
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
48.9%
Est. Net Flow (Q)
2026 Q2
10 / 97 positions shown
#SymbolCompanyTypeValue% Port.Shares1YYTD
1KRYSKRYSTAL BIOTECH INCSH$349.1M12.03%939,254
2CELCCELCUITY INCSH$178.3M6.14%1,704,318
3TGTXTG THERAPEUTICS INCSH$160.9M5.54%2,927,895
4PODDINSULET CORPSH$159.7M5.50%1,049,000
5NVCRNOVOCURE LTDSH$150.2M5.18%9,913,401
6UTHRUNITED THERAPEUTICS CORP DELSH$122.2M4.21%225,587
7INSPINSPIRE MED SYS INCSH$86.2M2.97%1,931,436
8RIGLRIGEL PHARMACEUTICALS INCSH$72.1M2.49%1,843,504
9ANIPANI PHARMACEUTICALS INCSH$71.8M2.48%867,760
10BBNXBETA BIONICS INCSH$68.8M2.37%4,393,714

The free plan shows the top 10 positions. The remaining 87 positions, the full portfolio and quarter changes unlock with Pro.

Pro Feature

This section is exclusive to Fundocap Pro. Full holdings tables, consensus trades, ownership analysis, backtests and exports unlock with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Soleus Capital Management, L.P. hold as of Q2 2026?

Soleus Capital Management, L.P. reported 97 positions worth $2.90B in its Q2 2026 13F filing. Largest positions: KRYS (12.0%), CELC (6.1%), TGTX (5.5%), PODD (5.5%) and NVCR (5.2%).

What did Soleus Capital Management, L.P. buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Soleus Capital Management, L.P. sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.